1029 related articles for article (PubMed ID: 26849806)
1. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis.
Pilebro B; Suhr OB; Näslund U; Westermark P; Lindqvist P; Sundström T
Ups J Med Sci; 2016; 121(1):17-24. PubMed ID: 26849806
[TBL] [Abstract][Full Text] [Related]
2. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis.
Hutt DF; Quigley AM; Page J; Hall ML; Burniston M; Gopaul D; Lane T; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Eur Heart J Cardiovasc Imaging; 2014 Nov; 15(11):1289-98. PubMed ID: 24939945
[TBL] [Abstract][Full Text] [Related]
3. Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition.
Arvidsson S; Pilebro B; Westermark P; Lindqvist P; Suhr OB
PLoS One; 2015; 10(11):e0143456. PubMed ID: 26600306
[TBL] [Abstract][Full Text] [Related]
4. The Utility of
Moore PT; Burrage MK; Mackenzie E; Law WP; Korczyk D; Mollee P
Heart Lung Circ; 2017 Nov; 26(11):1183-1190. PubMed ID: 28256403
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).
Pilebro B; Arvidsson S; Lindqvist P; Sundström T; Westermark P; Antoni G; Suhr O; Sörensen J
J Nucl Cardiol; 2018 Feb; 25(1):240-248. PubMed ID: 27645889
[TBL] [Abstract][Full Text] [Related]
6. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.
Rapezzi C; Quarta CC; Guidalotti PL; Pettinato C; Fanti S; Leone O; Ferlini A; Longhi S; Lorenzini M; Reggiani LB; Gagliardi C; Gallo P; Villani C; Salvi F
JACC Cardiovasc Imaging; 2011 Jun; 4(6):659-70. PubMed ID: 21679902
[TBL] [Abstract][Full Text] [Related]
7. Early-phase myocardial uptake intensity of
Abulizi M; Cottereau AS; Guellich A; Vandeventer S; Galat A; Van Der Gucht A; Plante-Bordeneuve V; Dubois-Randé JL; Bodez D; Rosso J; Damy T; Itti E
J Nucl Cardiol; 2018 Feb; 25(1):217-222. PubMed ID: 27804073
[TBL] [Abstract][Full Text] [Related]
8. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis.
Glaudemans AW; van Rheenen RW; van den Berg MP; Noordzij W; Koole M; Blokzijl H; Dierckx RA; Slart RH; Hazenberg BP
Amyloid; 2014 Mar; 21(1):35-44. PubMed ID: 24455993
[TBL] [Abstract][Full Text] [Related]
9. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.
Hutt DF; Fontana M; Burniston M; Quigley AM; Petrie A; Ross JC; Page J; Martinez-Naharro A; Wechalekar AD; Lachmann HJ; Quarta CC; Rezk T; Mahmood S; Sachchithanantham S; Youngstein T; Whelan CJ; Lane T; Gilbertson JA; Rowczenio D; Hawkins PN; Gillmore JD
Eur Heart J Cardiovasc Imaging; 2017 Dec; 18(12):1344-1350. PubMed ID: 28159995
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic contribution of DPD scintigraphy in transthyretin V30M cardiac amyloidosis.
Azevedo Coutinho MC; Cortez-Dias N; Cantinho G; Gonçalves S; Cunha N; Rodrigues T; Santos L; Conceição I; Agostinho J; Pinto FJ
Amyloid; 2024 Mar; 31(1):32-41. PubMed ID: 37493395
[TBL] [Abstract][Full Text] [Related]
11. Quantitative
Caobelli F; Braun M; Haaf P; Wild D; Zellweger MJ
J Nucl Cardiol; 2020 Oct; 27(5):1456-1463. PubMed ID: 31538322
[TBL] [Abstract][Full Text] [Related]
12. Cardiac transthyretin amyloidosis
Löfbacka V; Axelsson J; Pilebro B; Suhr OB; Lindqvist P; Sundström T
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1822-1832. PubMed ID: 33367948
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Quantitative
Harapoz M; Evans S; Geenty P; Kwok F; Stewart G; Taylor MS; Farlow D; Thomas L
Heart Lung Circ; 2022 Jun; 31(6):804-814. PubMed ID: 35181228
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of [
Caobelli F; Gözlügöl N; Bakula A; Rominger A; Schepers R; Stortecky S; Hunziker Munsch L; Dobner S; Gräni C
J Nucl Med; 2024 Jun; 65(6):944-951. PubMed ID: 38724281
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive risk stratification of patients with transthyretin amyloidosis.
Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
[TBL] [Abstract][Full Text] [Related]
16. Role of cardiac scintigraphy with ⁹⁹mTc-DPD in the differentiation of cardiac amyloidosis subtype.
de Haro-del Moral FJ; Sánchez-Lajusticia A; Gómez-Bueno M; García-Pavía P; Salas-Antón C; Segovia-Cubero J
Rev Esp Cardiol (Engl Ed); 2012 May; 65(5):440-6. PubMed ID: 22464102
[TBL] [Abstract][Full Text] [Related]
17. Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis-case report and literature review.
Ungericht M; Wanschitz J; Kroiss AS; Röcken C; Schuetz T; Messner M; Zaruba MM; Loescher WN; Poelzl G
J Nucl Cardiol; 2023 Aug; 30(4):1420-1426. PubMed ID: 35581484
[TBL] [Abstract][Full Text] [Related]
18. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition.
Suhr OB; Lundgren E; Westermark P
J Intern Med; 2017 Apr; 281(4):337-347. PubMed ID: 28093848
[TBL] [Abstract][Full Text] [Related]
19. Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis.
Gustafsson S; Ihse E; Henein MY; Westermark P; Lindqvist P; Suhr OB
Transplantation; 2012 May; 93(10):1017-23. PubMed ID: 22395298
[TBL] [Abstract][Full Text] [Related]
20.
Tahara N; Lairez O; Endo J; Okada A; Ueda M; Ishii T; Kitano Y; Lee HE; Russo E; Kubo T
ESC Heart Fail; 2022 Feb; 9(1):251-262. PubMed ID: 34841715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
